Tiziana Life Sciences Ltd. (TLSA)
Tiziana Life Sciences names new chief executive
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the appointment of Ivor Elrifi as its CEO, replacing acting CEO Gabriele Cerrone who will remain in his role as executive chairman of the board. The company highlighted that Elfiri previously served as the global head of the Patent Group at Cooley since 2014, and before that, he led the Patents division at Mintz Levin from 1999 to 2014.
Tiziana Life Sciences secures $3.4M in non-dilutive funding
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced it has received non-dilutive funding of $3.4 million which will be used to advance its investigation therapy foralumab. The company highlighted that foralumab is the only fully human anti-CD3 monoclonal antibody (mAb), which binds to the T cell receptor and dampens inflammation by modulating T cell function, therefore suppressing effector features in multiple immune cell subsets.
Tiziana Life Sciences secures FDA approval to dose first patient with moderate Alzheimer's with investigational therapy
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has won approval from the US Food and Drug Administration under an Expanded Access IND to dose its first patient with moderate Alzheimer's disease with its investigational therapeutic intranasal foralumab. Expanded access INDs allow patients to gain access to investigational drugs, biologics and medical devices to treat serious diseases and conditions for which there are no comparable or satisfactory therapy options outside of clinical trials, the biopharmaceutical company said.
Tiziana Life Sciences reports qualitative improvement in MS patients treated with lead asset
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled encouraing results from patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS) enrolled in its Expanded Access Program who have been receiving its drug asset foralumab for at least six months. The company is developing foralumab, the only fully human anti-CD3 mAb, which has demonstrated a favorable safety profile and clinical response in patients in studies to date.
Tiziana Life Sciences seeks funding from ALS Association for intranasal foralumab trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it along with its research partners at Mass General Hospital have been invited to apply for a prestigious grant from the ALS Association to fund a clinical trial evaluating its asset intranasal foralumab. The company said the grant is offered as part of the Hoffman ALS Clinical Trial Awards Program, which helps develop new and improved therapies for ALS by supporting early-stage clinical trials.
Tiziana Life Sciences' chief advisor to receive "Giants of MS" award
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the Chairman of its Scientific Advisory Board, Howard L Weiner, is to receive the “Giants of MS” award. The award ceremony will be held on May 30, 2024, during the Consortium of Multiple Sclerosis Centers annual meeting in Nashville, Tennessee.
